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Genetic variation in adducin, a protein associated with
the inner leaflet of the plasma membrane, may be in part
responsible for salt-sensitive hypertension. In the
Netherlands, 560 men who survived a myocardial infarc-
tion and 646 men who had undergone an orthopaedic
intervention participated in a case-control study. In men
in this study, the a-adducin polymorphism was not
associated with the risk of myocardial infarction either
among those with or among those without a clinical his-
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Introduction
Genetic variation in adducin, a protein associated
with the inner leaflet of the plasma membrane, may
be in part responsible for salt-sensitive hyperten-
sion.1 The Gly460 ! Trp polymorphism of an a-
adducin subunit is associated with hypertension in
French and Italian populations.2 Blood pressure
responses to acute salt-sensitivity tests and to
chronic diuretic therapy were more pronounced in
heterozygotes than in wild-type homozygotes.2 In a
Japanese population, however, the a-adducin poly-
morphism was not associated with hypertension3
even though the phenotype of salt-sensitivity has
been associated with an increased risk of cardio-
vascular events among Japanese patients with essen-
tial hypertension.4 Using data from a large Dutch
case-control study of myocardial infarction,5 we
examined the associations of the a-adducin poly-
morphism with level of blood pressure and risk of
myocardial infarction.
Subjects and methods
The methods have been described in detail.5 Briefly,
cases were men aged less than 70 years and hospital-
ised with first myocardial infarction in Leiden, The
Netherlands, between January 1990 and January
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tory of hypertension. In a cross-sectional analysis of
blood pressure data from the controls, the a-adducin
polymorphism was associated neither with self-reported
hypertension (OR = 0.78, 95% CI = 0.51–1.19) nor with
mean levels of systolic or diastolic blood pressure.
Additional studies in other populations are needed to
assess the contribution of a-adducin to high blood
pressure and cardiovascular risk.
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1996. Controls were men who had received prophy-
lactic anticoagulants briefly after an orthopaedic
intervention between January 1990 and May 1996.
The controls were frequency matched to the cases
within 10-year age groups. Controls were excluded
if they had had a previous myocardial infarction.
Subjects (case and controls) were excluded if they
had renal disease, severe neuropsychiatric prob-
lems, or a life expectancy of less than 1 year.
Response rates among eligible subjects were 84.3%
for cases and 77% for controls.
All subjects completed a risk-factor questionnaire
concerning cardiovascular risk factors such as smok-
ing, alcohol intake, medical history of hypertension,
and the use of selected medications. Blood pressure
was measured in a standardised fashion with the
person seated after 10 min rest during the visit when
the fasting blood sample was obtained. Using
published information,2 genetic analysis for the a-
adducin polymorphism was performed with a poly-
merase chain reaction (PCR) using a mutagenic
primer that introduced a BstXI site in the product of
the Trp-containing allele. The PCR-product of both
alleles contained an additional invariant BstXI-site
that was used as a positive control for the restriction
enzyme digestion.
Statistical analysis involved the use of odds ratios,
and analysis of variance was used for the blood
pressure levels.
Results
During the study period, 560 men who survived a
myocardial infarction and 646 men who had under-
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gone an orthopaedic intervention participated in
this case-control study. The mean age of the case
(56.2 years) did not differ from that of the controls
(57.3 years). As expected, traditional risk factors
such as smoking were associated with the risk of
myocardial infarction in this population.5 Self-
reported hypertension was also associated with the
risk of myocardial infarction (odds ratio (OR) = 1.84,
95% CI = 1.42–2.42).
Among 646 controls, 34.4% were heterozygous
and 5.9% were homozygous for the Trp460, variant
allele. In the analysis of the case-control data, sub-
jects without hypertension and with the wild-type
alleles for a-adducin served as the reference group
(Table 1). The a-adducin polymorphism was not
associated with the risk of myocardial infarction
either among those with or among those without
hypertension. Among subjects without hyperten-
sion, the presence of one or two variant alleles had
trivial effects on the risk of myocardial infarction
(OR = 0.94 for both groups). For subjects with self-
reported hypertension and the wild-type alleles for
a-adducin, compared with non-hypertensives with
the wild-type (the reference group), the risk of myo-
cardial infarction was 1.59 (95% CI = 1.12–2.26).
Among subjects with self-reported hypertension, the
presence of one or two variant alleles increased the
risk of myocardial infarction slightly from 1.59 for
the wild-type to 2.17 for heterozygotes and 2.09 for
homozygotes; but the differences between these
odds ratios and 1.59 were not statistically signifi-
cant. In the stratum of subjects with hypertension,
the presence of either one or two variant alleles com-
pared with the wild-type was only weakly associa-
ted with the risk of myocardial infarction
(OR = 1.36; 95% CI = 0.83–2.24).
In a cross-sectional analysis of data from the con-
trols, the a-adducin polymorphism was not associa-
ted with self-reported hypertension (OR = 0.78, 95%
CI = 0.51–1.19). While self-reported hypertension
was strongly associated with mean levels of systolic
and diastolic blood pressure (P , 0.001; Table 1),
the a-adducin polymorphism was not associated
with levels of systolic or diastolic blood pressure
(P . 0.1). Excluding subjects on antihypertensive
drug treatment and adjusting for age and calendar
year had trivial effects on the results. There was no
interaction between diuretic drug treatment and
genotype on blood pressure level.
Table 1 Association of a-adducin polymorphism with case-control status and blood pressure among controls
Hypertension a-adducin Cases Controls OR (95% CI) Controls
SBP DBP
No Wild-type 243 313 1.00 reference 137.5 86.6
Heterozygous 138 190 0.94 0.71–1.23 139.8 86.6
Homozygous 22 30 0.94 0.53–1.68 136.9 88.1
Yes Wild-type 90 73 1.59 1.12–2.26 157.6 96.2
Heterozygous 54 32 2.17 1.36–3.47 158.6 97.8
Homozygous 13 8 2.09 0.85–5.13 160.0 98.1
OR, odds ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure. For both SBP and DBP, the main effect of hypertension
was statistically significant (P , 0.001), but the main effect of a-adducin and the interaction terms were not (P . 0.1 for all tests).
Discussion
In this study from the Netherlands, the prevalence
of Trp460 variant allele of a-adducin was higher
than in French and Italian populations (23.5%
heterozygotes and 3.3% homozygotes among the
controls2). Previously associated with salt sensi-
tivity, the adducin polymorphism was not associa-
ted with the risk of myocardial infarction in this
study; and among controls, despite reasonable sam-
ple sizes, the adducin variant was not associated
with either self-reported hypertension or with level
of blood pressure.
In French and Italian populations, the Trp460
allele has been associated with both the occurrence
of hypertension and the response to diuretic ther-
apy.2 Several recent studies have suggested that the
a-adducin polymorphism affects renal sodium
handling in hypertension.6,7 Despite these persuas-
ive physiologic links, several other studies, like this
one, have failed to find an association between the
variant allele of a-adducin and hypertension in
Anglo-Australians8 and in Japanese patients.3,9,10
The a-adducin polymorphism may be in linkage dis-
equilibrium with other mutations that are respon-
sible for salt sensitivity or the risk of hypertension.
Issues related to control selection, case-fatality
rates, and the possibility of unmeasured or
unknown confounding factors remain potential
alternative explanations for findings, including null
findings, from case-control studies.
The a-adducin polymorphism is common; and if
it affects either the incidence of hypertension or the
response to diuretic therapy, this information would
be important from the point of view of public health.
Additional studies in other populations are needed
to assess the contribution of the a-adducin polymor-
phism to high blood pressure and cardiovascular
risk.
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